3-MeO-PCP: Difference between revisions

From TripSit wiki
Jump to navigation Jump to search
 
(5 intermediate revisions by 2 users not shown)
Line 1: Line 1:
3-Methoxyphencyclidine (3-MeO-PCP) is a dissociative anesthetic drug that is sold online as a research chemical.
[[File:3meopcp.jpg|right|3-MeO-PCP in a pill form]]


'''3-Methoxyphencyclidine''' (3-MeO-PCP) is a dissociative anesthetic drug that is sold online as a research chemical.
The effects are often described as being more euphoric and mentally clearer than many related compounds.
The effects are often described as being more euphoric and mentally clearer than many related compounds.


= History =
== History ==


A 1965 article published by Maddox described the synthesis of 2-MeO-PCP and 4-MeO-PCP. Preparation of 3-MeO-PCP was described later in 1979 by Geneste et al.
A 1965 article published by Maddox described the synthesis of 2-MeO-PCP and 4-MeO-PCP. Preparation of 3-MeO-PCP was described later in 1979 by Geneste et al.
Line 9: Line 10:
The compound was first synthesized in 1979 to investigate the structure-activity relationship of phencyclidine derivatives. The activity of 3-MeO-PCP in man was not described until 1999 when a chemist using the pseudonym John Q. Beagle wrote that 3-MeO-PCP was qualitatively similar to PCP with comparable potency.
The compound was first synthesized in 1979 to investigate the structure-activity relationship of phencyclidine derivatives. The activity of 3-MeO-PCP in man was not described until 1999 when a chemist using the pseudonym John Q. Beagle wrote that 3-MeO-PCP was qualitatively similar to PCP with comparable potency.


= Dosage =
== Dosage ==


3-MeO-PCP, like PCP is active in the single milligram range and therefor can be hard to accurately measure.
3-MeO-PCP, like PCP is active in the single milligram range and therefor can be hard to accurately measure.
Line 28: Line 29:


| Light || 3-5 mg
| Light || 3-5 mg
|-
| Common || 5-10 mg
|-
| Strong || 10-15 mg
|-
| Heavy || 15-18 mg+
|}
{| class="wikitable"
|+ Insufflated
|-
| Threshold || 1-2 mg
|-
| Light || 2-5 mg


|-
|-
Line 36: Line 63:


| Strong || 8-12 mg
| Strong || 8-12 mg
|-
| Heavy || 12-15 mg+


|}
|}
Line 51: Line 82:
|-
|-


| Total || 4-6 hours
| Total || 3-5 hours +/- 60 minutes, dependent on dose.


|-
|-
Line 59: Line 90:
|}
|}


Insufflated onset is approximately 5-15 minutes and the duration is a bit shorter.
{| class="wikitable"
 
|+ Insufflated
 
|-
 
| Onset || 10-30 minutes
 
|-
 
| Total || 2-4 hours +/- ~30 minutes, dependent on dose.
 
|-
 
| After-effects || 2-48 hours
 
|}


= Effects =
== Effects ==


== Positive ==
=== Positive ===


* Increase in energy / stimulation
* Increase in energy / stimulation
Line 83: Line 130:
* Shifts in perception of reality
* Shifts in perception of reality


== Neutral ==
=== Neutral ===


* Increased heart rate (lower doses)
* Increased heart rate (lower doses)
Line 101: Line 148:
* Confusion, disorientation
* Confusion, disorientation


== Negative ==
=== Negative ===


* Disturbing hallucinations and/or delusions
* Disturbing hallucinations and/or delusions
Line 119: Line 166:
* Severe distortion or loss of auditory/visual perception
* Severe distortion or loss of auditory/visual perception


= Harm Reduction =
== Harm Reduction ==


* 3-Meo-PCP is a very powerful NMDA antagonist (doses are on par with [[PCP]]), and as such it has the potential to be very confusing.
* 3-Meo-PCP is a very powerful NMDA antagonist (doses are on par with [[PCP]]), and as such it has the potential to be very confusing.
Line 127: Line 174:
* It is difficult to measure 3-MeO-PCP accurately with a scale because it is active in the 1-10 mg range. See [http://wiki.tripsit.me/wiki/3-MeO-PCP#Dosage the dosage section] for more information.
* It is difficult to measure 3-MeO-PCP accurately with a scale because it is active in the 1-10 mg range. See [http://wiki.tripsit.me/wiki/3-MeO-PCP#Dosage the dosage section] for more information.
* 3-MeO-PCP has a steep dose-response-curve and an onset ranging from approximately 20-40 minutes. It is inadvisable to redose, especially within the first hour.
* 3-MeO-PCP has a steep dose-response-curve and an onset ranging from approximately 20-40 minutes. It is inadvisable to redose, especially within the first hour.


For more information see [http://wiki.tripsit.me/wiki/Dissociatives#Harm_Reduction Dissociative Harm-Reduction].
For more information see [http://wiki.tripsit.me/wiki/Dissociatives#Harm_Reduction Dissociative Harm-Reduction].


 
=== Interactions ===
== Interactions ==


Check out our [[Drug Combinations]] page and chart for interactions and combinations of common drugs.  
Check out our [[Drug Combinations]] page and chart for interactions and combinations of common drugs.  
Line 139: Line 184:
Specifically, do not mix 3-MeO-PCP with alcohol or benzodiazepines. 3-MeO-PCP will also likely produce synergistic effects if used in conjunction with certain serotogenic medications or drugs.
Specifically, do not mix 3-MeO-PCP with alcohol or benzodiazepines. 3-MeO-PCP will also likely produce synergistic effects if used in conjunction with certain serotogenic medications or drugs.


 
== Chemistry and Pharmacology ==
= Chemistry and Pharmacology =


3-MeO-PCP binds to the NMDA receptor with higher affinity than PCP and has the highest affinity of the three isomeric anisyl-substitutions, followed by 2-MeO-PCP and 4-MeO-PCP. It is also a Serotonin Reuptake Inhibitor (SRI).
3-MeO-PCP binds to the NMDA receptor with higher affinity than PCP and has the highest affinity of the three isomeric anisyl-substitutions, followed by 2-MeO-PCP and 4-MeO-PCP. It is also a Serotonin Reuptake Inhibitor (SRI).
Line 148: Line 192:
3-MeO-PCP has a Ki of 20 nM for the NMDA receptor, 216 nM for the serotonin transporter and 42 for the sigma1 receptor.
3-MeO-PCP has a Ki of 20 nM for the NMDA receptor, 216 nM for the serotonin transporter and 42 for the sigma1 receptor.


= Legal status=
== Legal status ==


UK: Class B, as are all arylcyclohexamines.
UK: Class B, as are all arylcyclohexamines.
Line 154: Line 198:
US: Covered by the analogue act if sold for human consumption.
US: Covered by the analogue act if sold for human consumption.


= Links =
== Links ==


[https://en.wikipedia.org/wiki/3-MeO-PCP Wikipedia]
[https://en.wikipedia.org/wiki/3-MeO-PCP Wikipedia]
Line 165: Line 209:


[[Category:Dissociative]]
[[Category:Dissociative]]
[[category:Research Chemical]]

Latest revision as of 18:11, 14 March 2015

3-MeO-PCP in a pill form
3-MeO-PCP in a pill form

3-Methoxyphencyclidine (3-MeO-PCP) is a dissociative anesthetic drug that is sold online as a research chemical. The effects are often described as being more euphoric and mentally clearer than many related compounds.

History

A 1965 article published by Maddox described the synthesis of 2-MeO-PCP and 4-MeO-PCP. Preparation of 3-MeO-PCP was described later in 1979 by Geneste et al.

The compound was first synthesized in 1979 to investigate the structure-activity relationship of phencyclidine derivatives. The activity of 3-MeO-PCP in man was not described until 1999 when a chemist using the pseudonym John Q. Beagle wrote that 3-MeO-PCP was qualitatively similar to PCP with comparable potency.

Dosage

3-MeO-PCP, like PCP is active in the single milligram range and therefor can be hard to accurately measure.

Most if not all consumer-grade jewelry-scales advertised as working at the 0.001g (mg) range are not reliably accurate enough to measure quantities weighing less than around 15-25 mg depending on the model and calibration. With a drug as potent as 3-MeO-PCP a small discrepancy in measurement can make a world of difference in physical and mental response to the dose. It is for these reasons that it would be in one's best interest to use a volumetric dose measurement technique as outlined in this guide.

Oral
Threshold 1.5-3 mg
Light 3-5 mg
Common 5-10 mg
Strong 10-15 mg
Heavy 15-18 mg+
Insufflated
Threshold 1-2 mg
Light 2-5 mg
Common 5-8 mg
Strong 8-12 mg
Heavy 12-15 mg+

Duration

Oral
Onset 20-40 minutes
Total 3-5 hours +/- 60 minutes, dependent on dose.
After-effects 2-48 hours
Insufflated
Onset 10-30 minutes
Total 2-4 hours +/- ~30 minutes, dependent on dose.
After-effects 2-48 hours

Effects

Positive

  • Increase in energy / stimulation
  • Euphoria
  • Pleasant mental and/or body high
  • Music appreciation
  • Disconnected thoughts
  • Sense of calm
  • Increased sociability, loss of inhibitions
  • Closed and open-eye visuals
  • Shifts in perception of reality

Neutral

  • Increased heart rate (lower doses)
  • Altered time perception
  • Disrupted speech patterns
  • Analgesia (decreased pain awareness) and numbness
  • Distorted sensory perceptions, hallucinations
  • Unusual and unpredictable behavior
  • Mild to moderate dissociation
  • Confusion, disorientation

Negative

  • Disturbing hallucinations and/or delusions
  • Anxiety, paranoia
  • Severe dissociation, depersonalization
  • Ataxia (loss of motor coordination)
  • Psychotic episodes
  • Nausea, vomiting
  • Temporary amnesia
  • Severe distortion or loss of auditory/visual perception

Harm Reduction

  • 3-Meo-PCP is a very powerful NMDA antagonist (doses are on par with PCP), and as such it has the potential to be very confusing.
  • 3-MeO-PCP is considered to be a 'research-chemical', simply meaning that there is little to no clinical data on long-term effects.
  • 3-MeO-PCP, as with all arylcyclohexylamine class dissociative compounds may cause neurotoxicity when used frequently or in high dose.
  • 3-MeO-PCP acts as a mild Serotonin Reuptake Inhibitor and as such may risk adverse effects as a result of synergy when used with certain serotogenic drugs or medications. See Interactions.
  • It is difficult to measure 3-MeO-PCP accurately with a scale because it is active in the 1-10 mg range. See the dosage section for more information.
  • 3-MeO-PCP has a steep dose-response-curve and an onset ranging from approximately 20-40 minutes. It is inadvisable to redose, especially within the first hour.

For more information see Dissociative Harm-Reduction.

Interactions

Check out our Drug Combinations page and chart for interactions and combinations of common drugs. PCP and 3-MeO-PCP have similar profiles and as such its safe to assume the PCP combination-chart data also applies to 3-MeO-PCP.

Specifically, do not mix 3-MeO-PCP with alcohol or benzodiazepines. 3-MeO-PCP will also likely produce synergistic effects if used in conjunction with certain serotogenic medications or drugs.

Chemistry and Pharmacology

3-MeO-PCP binds to the NMDA receptor with higher affinity than PCP and has the highest affinity of the three isomeric anisyl-substitutions, followed by 2-MeO-PCP and 4-MeO-PCP. It is also a Serotonin Reuptake Inhibitor (SRI).

3-MeO-PCP hydrochloride is a white crystalline solid with a melting point of 204-205°C.

3-MeO-PCP has a Ki of 20 nM for the NMDA receptor, 216 nM for the serotonin transporter and 42 for the sigma1 receptor.

Legal status

UK: Class B, as are all arylcyclohexamines.

US: Covered by the analogue act if sold for human consumption.

Links

Wikipedia

Interview with a Ketamine Chemist

From MXE to PCP